Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Al amyloidosis.
Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales. Desport E, et al. Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Orphanet J Rare Dis. 2012. PMID: 22909024 Free PMC article. Review.
[Current treatment of AL amyloidosis].
Desport E, Moumas E, Abraham J, Delbès S, Lacotte-Thierry L, Touchard G, Fermand JP, Bridoux F, Jaccard A. Desport E, et al. Nephrol Ther. 2011 Nov;7(6):467-73. doi: 10.1016/j.nephro.2011.02.003. Epub 2011 Apr 15. Nephrol Ther. 2011. PMID: 21497573 Review. French.
Hepatocyte growth factor measurement in AL amyloidosis.
Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A. Abraham J, et al. Among authors: desport e. Amyloid. 2015;22(2):112-6. doi: 10.3109/13506129.2015.1014548. Epub 2015 Jun 8. Amyloid. 2015. PMID: 26053104
Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex.
Penot A, Abraham J, Debarri H, Desport E, Aguilar C, Lavergne D, Auroy F, Leleu X, Goldstein A, Kolb B, Bridoux F, Fermand JP, Leblond V, Jaccard A. Penot A, et al. Among authors: desport e. Amyloid. 2011 Jun;18 Suppl 1:145-7. doi: 10.3109/13506129.2011.574354054. Amyloid. 2011. PMID: 21838466 Clinical Trial. No abstract available.
[AL amyloidosis].
Jaccard A, Desport E, Mohty D, Bridoux F. Jaccard A, et al. Among authors: desport e. Rev Med Interne. 2015 Feb;36(2):89-97. doi: 10.1016/j.revmed.2014.08.003. Epub 2014 Sep 5. Rev Med Interne. 2015. PMID: 25194219 Review. French.
[New insights in the treatment of myeloma with renal failure].
Moumas E, Hanf W, Desport E, Abraham J, Delbès S, Debiais C, Lacotte-Thierry L, Touchard G, Jaccard A, Fermand JP, Bridoux F. Moumas E, et al. Among authors: desport e. Nephrol Ther. 2011 Nov;7(6):457-66. doi: 10.1016/j.nephro.2011.03.002. Epub 2011 Apr 23. Nephrol Ther. 2011. PMID: 21515102 Review. French.
New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis.
Colombat M, Aldigier JC, Rothschild PR, Javaugue V, Desport E, Frouget T, Goujon JM, Rioux-Leclercq N, Quellard N, Rerolle JP, Paraf F, Beugnet C, Tiple A, Durrbach A, Samuel D, Brézin A, Bridoux F, Valleix S. Colombat M, et al. Among authors: desport e. Kidney Int. 2020 Jul;98(1):195-208. doi: 10.1016/j.kint.2020.03.033. Epub 2020 Apr 23. Kidney Int. 2020. PMID: 32571483
[Classification and therapeutic management of monoclonal gammopathies of renal significance].
Javaugue V, Bouteau I, Sirac C, Quellard N, Diolez J, Colombo A, Desport E, Ecotière L, Goujon JM, Fermand JP, Touchard G, Jaccard A, Bridoux F. Javaugue V, et al. Among authors: desport e. Rev Med Interne. 2018 Mar;39(3):161-170. doi: 10.1016/j.revmed.2017.03.012. Epub 2017 Apr 27. Rev Med Interne. 2018. PMID: 28457684 Review. French.
39 results